


Donor 2777

Genetic Testing Summary



Last Updated: 06/11/20

Donor Reported Ancestry: Spanish, African, Chinese

Jewish Ancestry: No

Genetic Test*	Result	Comments/Donor's Residual Risk**

Chromosome analysis (karyotype)	Normal male karyotype	No evidence of clinically significant chromosome abnormalities
Hemoglobin evaluation	Normal hemoglobin fractionation and MCV/MCH results	Reduced risk to be a carrier for sickle cell anemia, beta thalassemia, alpha thalassemia trait (aa/ and a-/a-) and other hemoglobinopathies
Cystic Fibrosis (CF) carrier screening	Negative by genotyping for 99 mutations in the CFTR gene	1/190
Spinal Muscular Atrophy (SMA) carrier screening	Negative for deletions of exon 7 in the SMN1 gene	1/720
Beta-Globin Hemoglobinopathies (HBB)	Negative by genotyping for 28 mutations in the HBB gene	Beta Thalassemia 1/250 Sickle Cell Disease <1/500

*No single test can screen for all genetic disorders. A negative screening result significantly reduces, but cannot eliminate, the risk for these conditions in a pregnancy.

**Donor residual risk is the chance the donor is still a carrier after testing negative.





Male Name: DONOR 2777 DOB: 🕻 Ethnicity: East Asian Sample Type: EDTA Blood Date of Collection: 10/10/2011 Barcode: Indication: Egg or Sperm Donor Female Not tested

Counsyl Test Results (Egg or Sperm Donor)

The Counsyl test uses targeted DNA mutation analysis to simultaneously determine the carrier status of an individual for a number of Mendelian diseases. This report indicates which mutations, if any, were detected for each mutation panel. Because only select mutations are tested, the percentage of carriers detected varies by ethnicity. A negative test result does not eliminate the possibility that the individual is a carrier. Interpretation is given as an estimate of the risk of conceiving a child affected with a disease, which is based on reported ethnicity, the test results, and an assumption of no family history.*



DONOR 2777

DONOR 2777's DNA test shows that he is not a carrier of any disease-causing mutation tested.

Partner

The reproductive risk presented is based on a hypothetical pairing with a partner of the same ethnic group.

Reproductive Risk Summary

No increased reproductive risks to highlight. Please refer to the following pages for detailed information about the results.

Clinical notes:

Individuals of African, Southeast Asian, and Mediterranean ancestry are at increased risk for being carriers for hemoglobinopathies and may also benefit from carrier testing by CBC and hemoglobin electrophoresis or HPLC. ACOG Practice Bulletin No. 78. Obstet ٠ Gynecol 2007;109:229-37.

To schedule a free appointment to speak with a genetic counselor about your results, please visit www.counsyl.com/appointment.

•Limitations: In an unknown number of cases, nearby genetic variants may interfere with mutation detection. Other possible sources of diagnostic error include sample mix-up, trace contamination, and technical errors. The reproductive risk summary is provided as an aid to genetic counseling. Inaccurate reporting of ethnicity may cause errors in risk calculation.

This test was developed and its performance characteristics determined by Counsyl, Inc. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test is used for clinical purposes, it should not be regarded as investigational or for research. These results are adjunctive to the ordering physician's workup. CLIA Number: #05D1102604: Lab Directors: Jessica Jacobson, MD, William K. Seltzer, PhD, FACMG Page 1 of 2



2200 Bridge Parkway, Suite 103, Redwood City, CA 94065 (888) COUNSYL | http://www.counsyl.com

Version: 1.6.89



Male Name: DONOR 2777 DOB: Female Not tested

Full Results

Below are the full test results for all diseases on the panel. Noted are the specific genetic mutations for which the patient tested positive or negative. If there was insufficient data to determine the genotype for any variant, this will be noted as "no call." Also listed in this section is the patient's post-test risk of being a carrier of each disease as well as the odds that his future children could inherit each disease.

Beta Thalassemia	Reproductive risk: 1 in 31,000	Risk before testing: 1 in 3,900	Reduced sisk
DONOR 2777: No mutations detected. This does not rule out the pr assuming a negative family history, is 1 in 250. 87% detection rate.	ossibility of being a carrier of untested r	nutations. The post-test risk of b	eing a carrier,
Gene: HBB. Variants (27): K17X, Q39X, Phe41fs, Ser9fs, IVS-II-654, IVS-II-745, IV IVS-II-849(A>G), Gly24 T>A, -87C>G, Hb C, W15X, Gly16fs, Glu6fs, Hb E, Hb D-Pu	15-11-850, IVS-1-6, IVS-1-110, IVS-1-5, IVS-1-1(G>A injab, Hb O-Arab. anvenuence and a construction of the operation	1), -88C>T, -28A>G, -29A>G, Lys8fs, Ph	e71fs, IVS-II-849(A>C),
Cystic Fibrosis	Reproductive risk: 1 in 66,000	Risk before testing: 1 in 30,000	Resuced figh
DONOR 2777: No mutations detected. This does not rule out the passuming a negative family history, is 1 in 190. 54% detection rate.	1993년 2013년 - 1월 1997년 - 1997년 - 1997년 - 1997년 - 1997년 - 1997		
Gene: CFTR. Variants (99): G85E, R117H, R334W, R347P, A455E, G542X, G551I 1717-1G>A, 1898+1G>A, 2789+5G>A, 3120+1G>A, 3849+16kbC>T, E60X, R75X, 1078deiT, 3876delA, 3905insT, 1812-1G>A, 3272-26A>G, 2183AA>G, S549R(A>C) K710X, R764X, Q890X, R1068C, W1089X, Y1092X, R1158X, S1196X, W1204X(C3 2043deiG, 2055del9>A, 2108delA, 3171delC, 3667del4, 3791delC, 1288insTA, 218- 1888+5G>T, 3120G>A, 457TAT>G, 3849+4A>G, Q359K/T360K.	E92X, Y122X, G178R, R347H, Q493X, V520F, S), R117C, L206W, G330X, T338I, R352Q, S364P 3611G5A), D1238Y, S1251N, S1255X, 3199del6	549N, P574H, MT10TK, D1152H, 2145 , G480C, C524X, S549R(T>G), Q552X, 574deJA 663delT, 935delA 936delTA.	A559T, G622D, R709X, 1677delTA, 1949del84,
Sickle Cell Disease	Reproductive risk: Less than 1 in 1,000,000	Risk before testing: less than 1 in 1,000,000	Reduced rish
DONOR 2777: No mutations detected. This does not rule out the prassuming a negative family history, is < 1 in 500. 55% detection rate	ossibility of being a carrier of untested r e.	nutations. The post-test risk of b	eing a carrier,
Gene: HBB. Variants (28): Hb S, K17X, Q39X, Phe41fs, Ser9fs, IVS-II-654, IVS-II-7 II-849(A>C), IVS-II-849(A>G), Gly24 T>A, -87C>G, Hb C, W15X, Gly16fs, Glu6fs, H	745, IVS-II-850, IVS-I-6, IVS-I-110, IVS-I-5, IVS-I- b E, Hb D-Punjab, Hb O-Arab.	-{{G>A}, -88C>T, -28A>G, -29A>G, Lys{	its, Phe71fs, IVS-
Spinal Muscular Atrophy	Reproductive risk: 1 in 150,000	Risk before testing: 1 in 11,000	Reduced fish
DONOR 2777: No mutations detected. This does not rule out the po assuming a negative family history, is 1 in 720. 93% detection rate.	ossibility of being a carrier of untested r	nutations. The post-test risk of b	eing a carrier,

Gene: SMN1. Variants (1): Exon 7 deletion.

This test was developed and its performance characteristics determined by Counsyl, Inc. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test is used for clinical purposes. It should not be regarded as investigational or for research. These results are adjunctive to the ordering physician's workup. CLIA Number: #05D1102604. Lab Directors: Jassica Jacobson, MD, William K. Seltzer, PhD, FACMG.